“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: OpGen
OpGen is primarily a lab diagnostic manufacturer focused on identifying and treating bacterial infections. It has the technology to detect pathogens and predict resistance. Through the dual platform offering of the AMR Gene Panel and Unyvero, it can provide diagnostic results in hours instead of days.
OpGen — 5 videos in collection
OpGen (Nasdaq CM: OPGN) has announced encouraging top-line data from its Unyvero urinary tract infection (UTI) panel trial.
The Unyvero UTI panel is a diagnostic test designed to detect pathogens and antimicrobial resistance markers related to UTI from native urine specimens without the need for culturing, bringing test times down to less than five hours.
In this video, Edison Group Managing Director, Soo Romanoff and OpGen’s CEO, Oliver Schacht, discuss the significance of the trial data and OpGen’s future plans.
Get access to the very latest content matched to your personal investment style.
